A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Saquinavir (Drug); Lamivudine (Drug); Zidovudine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Hoffmann-La Roche
Summary
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus
lamivudine.
Clinical Details
Official title: A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
Study design: Treatment, Safety Study
Detailed description:
A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus
lamivudine until the completion of the analysis after at least 4 weeks of therapy.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- HIV antibody positive.
- CD4 count >= 150 and <= 500 cells/mm3.
Exclusion Criteria
Prior Medication:
Excluded:
- Prior antiretroviral therapy.
- Prior protease inhibitor therapy.
Locations and Contacts
Davies Med Ctr / c/o HIV Institute, San Francisco, California 94114, United States
Pacific Oaks Med Group / Rsch & Scientific Investigation, Sherman Oaks, California 91403, United States
Columbia Presbyterian Med Ctr, New York, New York 10032, United States
Additional Information
Last updated: June 23, 2005
|
